Today, Solid Biosciences announced that the first participant has been dosed in the Phase 3 Impact Duchenne clinical trial, a randomised, double-blind, placebo-controlled study evaluating SGT-003 for Duchenne.

Clinical trial sites are currently active in Australia and Canada, and additional site activations in the UK and US are expected in the second half of 2026, with sites in the EU anticipated to follow, subject to regulatory clearances. Solid has also shared that 46 participants have been dosed in the ongoing Phase 1/2 Inspire Duchenne clinical trial.

Click here to read the full press release for more details.